Endocrine treatment potentiates antigen presentation and in combination with SMAC mimetics enhances an anti-tumor immune response in hormone receptor positive breast cancer (RNA-seq)
Ontology highlight
ABSTRACT: To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:To investigate the effects of endocrine treatment in combination with SMAC mimetics in ER+ breast cancer on tumor cell response to IFNg
Project description:Macrophages engulf apoptotic bodies and cellular debris as part of homeostasis, but they can also phagocytosis live cells such as aged red blood cells. Pharmacologic reprogramming with the SMAC mimetic LCL-161 in combination with T cell-derived cytokines can induce macrophages to phagocytosis live cancer cells in mouse models. Here we extend these findings to encompass a wide range of monovalent and bivalent SMAC mimetic compounds, demonstrating that live cell phagocytosis is a class effect of these agents. We demonstrate robust phagocytosis of live pancreatic and breast cancer cells by primary human macrophages across a range of healthy donors. Unlike mouse macrophages where combination of SMAC mimetics with lymphotoxin enhanced phagocytosis, human macrophages were more efficiently polarized to phagocytose live cells by the combination of SMAC mimetics and IFNg. We profiled phagocytic macrophages by transcriptional and proteomic methodologies, uncovering a positive feedback loop of autocrine TNFa production.
Project description:Endocrine treatment potentiates antigen presentation and in combination with SMAC mimetics enhances an anti-tumor immune response in hormone receptor positive breast cancer
Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFα-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells. SCID mice with MDA-MB-231 xenograft tumors were treated with 5 mg/kg of SM-164 intravenously for 5 days/week for 2 weeks. SM-164-regressed MDA-MB-231 tumors regrew after treatment ended. Tumor cells from these regrown MDA-MB-231 tumors were isolated and total RNAs were prepared for microarray analysis.
Project description:Endocrine treatment potentiates antigen presentation and in combination with SMAC mimetics enhances an anti-tumor immune response in hormone receptor positive breast cancer (orig)